PIII-19The influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin von HE, Y, SABO, R, WANG, Y, CAMPESTRINI, J, RIVERE, G, SALTZMAN, M, LIGUEROSSAYLAN, M

Volltext

PII-12Absolute bioavailability of vildagliptin in healthy subjects von HE, Y, SABO, R, BALEZ, S, WANG, Y, CAMPESTRINI, J, MARION, A, LIGUEROSSAYLAN, M

Volltext

PIII-16Lack of pharmacokinetic interaction between Vildagliptin and Metformin in patients with type 2 diabetes von HE, Y, SABO, R, PICARD, F, WANG, Y, CAMPESTRINI, J, HERRON, J, LIGUEROSSAYLAN, M

Volltext

Lack of effect of LAF237 on C-peptide clearance in patients with type 2 diabetes von He, Y. L., Horowitz, A., Watson, C., Foley, J., Sallas, W., Ligueros‐Saylan, M.

Volltext

Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes von He, Y. L., Balch, A., Campestrini, J., Rivere, G. J., Serra, D., Prasad, P., Ligueros‐Saylan, M.

Volltext

Assessment of ethnic differences in the pharmacokinetics of valsartan von Sunkara, G., Thang‐Dittman, C., Yeh, C., Ligueros‐Saylan, M., Prasad, P., Masuda, N., Koseki, N., Fukui, Y.

Volltext